Patient-Derived Xenograft Models of Pancreatic Cancer
Patient-derived xenograft (PDX) models provide a predictive preclinical model for the evaluation of an agent’s efficacy prior to entering the clinic. The CrownBio pancreatic collection contains over 100 models, including models of both North American and Asian descent. More
Benefits of CrownBio’s Pancreatic Cancer PDX Models
Our pancreatic cancer patient-derived xenograft models offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, Patient derived xenografts reflect the heterogeneity and diversity of the human patient population. PDX will give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® Pancreatic cancer PDX model collection is well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.